Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AZN | 6-K | neutral | 2/10 | AstraZeneca filed a Form 6-K reporting the vesting of a long-term performance share award to CFO Aradhana Sarin. The awa | Aug 19, 2026 |
| MREO | 8-K | bearish | 7/10 | Mereo BioPharma received a second Nasdaq notice granting an additional 180-day compliance period (until February 16, 202 | Aug 19, 2026 |
| GILD | COURT-RULING | bullish | 7/10 | The Fourth Circuit affirmed a preliminary injunction in favor of Gilead Sciences, blocking the importation and sale of f | Aug 19, 2026 |
| SNY | COURT-RULING | bullish | 4/10 | Sanofi won dismissal with prejudice of a product liability lawsuit over its drug Rezurock (belumosudil). The court grant | Aug 19, 2026 |
| CMMB | PRESS-RELEASE | bearish | 6/10 | Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no revenue. The planned m | Aug 19, 2026 |
| ANL | 6-K | neutral | 3/10 | Adlai Nortye Group Ltd. (formerly Adlai Nortye Ltd.) completed its redomiciliation from the Cayman Islands to Singapore, | Aug 19, 2026 |
| ASBP | 8-K | neutral | 2/10 | Aspire Biopharma Holdings, Inc. filed an 8-K on August 19, 2026, solely to announce the distribution of an investor pres | Aug 19, 2026 |
| ETST | 8-K | neutral | 3/10 | Earth Science Tech, Inc. (ETST) acquired Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients, from | Aug 19, 2026 |
| HUMA | PRESS-RELEASE | bullish | 6/10 | Humacyte announced publication of one-year Phase 3 V007 trial results in The Lancet Digital Health, showing ATEV superio | Aug 19, 2026 |
| AEON | PRESS-RELEASE | bullish | 6/10 | AEON Biopharma released expanded primary structure and preliminary disulfide bond data for its ABP-450 biosimilar candid | Aug 19, 2026 |
| IMRN | 6-K | neutral | 4/10 | Immuron reported FY2026 global sales of A$7.7 million (+6% YoY) and cash of A$10.0 million in its Emerging Growth Confer | Aug 19, 2026 |
| NTHI | CLUSTER | bullish | 5/10 | Two CEOs at NEONC TECHNOLOGIES (NTHI) made open-market purchases totaling $175K over a 7-day window, with the largest si | Aug 19, 2026 |
| RLAY | CLUSTER | bearish | 5/10 | Relay Therapeutics' CEO and CFO sold a combined $1.33M in open-market sales over a 4-day window, representing ~0.03% of | Aug 19, 2026 |
| LLY | CLUSTER | neutral | 3/10 | Two senior executives at Eli Lilly sold a combined $10.01M in stock over the past week, including the EVP of Internation | Aug 19, 2026 |
| ELAN | CLUSTER | bullish | 4/10 | Two ELAN insiders, Director Michael J. Harrington and General Counsel Shiv O'Neill, made open-market purchases totaling | Aug 19, 2026 |
| ZLAB | CLUSTER | neutral | 2/10 | A small insider selling cluster at Zai Lab involved a director selling $213K in open-market shares and the CFO surrender | Aug 19, 2026 |
| RYTM | CLUSTER | bearish | 6/10 | A cluster of insider selling at Rhythm Pharmaceuticals, totaling $9.95M in open-market sales across four senior executiv | Aug 19, 2026 |
| CSTL | CLUSTER | neutral | 3/10 | The CEO and CFO of Castle Biosciences collectively sold ~$775K in open-market stock on August 14, 2026. The CFO's sale o | Aug 19, 2026 |
| CORT | CLUSTER | bearish | 4/10 | Three Corcept insiders, including the Chief Business Officer and Chief Development Officer, sold a total of $1.82M in op | Aug 19, 2026 |
| MANE | CLUSTER | neutral | 3/10 | CEO Reid Alexander and Director John Childs sold a combined $2.82M in open-market MANE shares within a week of Veradermi | Aug 18, 2026 |
| ASND | INSIDER-BUY | neutral | 3/10 | Director Jean Jacques Bienaime purchased $493K of ASND stock in two open-market transactions on August 14, 2026, at ~$24 | Aug 18, 2026 |
| MGTX | 144 | neutral | 3/10 | Director Alexandria Forbes filed a Form 144 giving notice of intent to sell 62,000 ordinary shares of MeiraGTx Holdings | Aug 18, 2026 |
| STOK | CLUSTER | neutral | 3/10 | Two Stoke Therapeutics insiders, a director and the general counsel, executed open-market sales totaling $469K on August | Aug 18, 2026 |
| GILD | CLUSTER | neutral | 2/10 | Two GILD C-suite executives (CFO and Chief Communications & Corporate Affairs Officer) sold a combined $2.69M in open-ma | Aug 18, 2026 |
| VIR | COURT-RULING | neutral | 1/10 | A joint stipulation in Smith v. Vir Biotechnology, Inc. was approved by the court, extending the mediation deadline from | Aug 18, 2026 |
| IRON | CLUSTER | neutral | 2/10 | CEO John Quisel and COO Jonathan Yu sold a combined $723K in open-market shares following derivative exercises. The CEO' | Aug 18, 2026 |
| JNJ | CLUSTER | neutral | 2/10 | CEO Joaquin Duato and EVP Jennifer Taubert sold a combined $30.65M in open-market stock over a 5-day window, with Duato' | Aug 18, 2026 |
| ADPT | 144 | neutral | 3/10 | Director Robert Hershberg filed a Form 144 to sell 30,664 shares of Adaptive Biotechnologies (ADPT) with an estimated ma | Aug 18, 2026 |
| LIMN | 8-K | bearish | 7/10 | Liminatus Pharma filed an 8-K confirming a 1-for-50 reverse stock split to regain compliance with Nasdaq's $1.00 minimum | Aug 18, 2026 |
| VREOF | 8-K | neutral | 3/10 | Vireo Growth Inc. announced a Normal Course Issuer Bid (NCIB) authorizing the repurchase of up to 2,426,872 subordinate | Aug 18, 2026 |